Literature DB >> 21569056

Predictors of acute and long-term success of slow pathway ablation for atrioventricular nodal reentrant tachycardia: a single center series of 1,419 consecutive patients.

Alexander Feldman1, Aleksandr Voskoboinik, Saurabh Kumar, Steven Spence, Joseph B Morton, Peter M Kistler, Paul B Sparks, Jitendra K Vohra, Jonathan M Kalman.   

Abstract

BACKGROUND: Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common mechanism of supraventricular tachycardia. Slow pathway (SP) ablation is the first-line treatment approach with a high acute success rate and a low risk of inadvertent complete atrioventricular (AV) block. However, there is still some uncertainty as to the most appropriate procedural endpoints and the impact of these on risk of recurrence. We report the acute and long-term results of SP ablation in a large single-center consecutive series and analyze predictors of acute success and late recurrence.
METHODS: The study included 1,448 consecutive procedures in 1,419 patients with AVNRT (mean age 49 ± 17 years, 66% women) who underwent SP ablation using a combined electrophysiologic and anatomic approach. Univariate and multivariate analysis was performed for potential predictors of acute success and late recurrence.
RESULTS: Acute success was achieved in 98.1%. Transient (first, second, or third degree) AV block occurred during the procedure in 20 (1.41%) patients. One patient (0.07%) had persistent first-degree and transient second-degree AV block after ablation and underwent pacemaker implant at day 21. Of the 1,391 patients with successful ablation, 22 patients (1.5%) developed AVNRT recurrence during a follow-up period of 63 ± 38 months. The only independent predictor of reduced procedural success was the presence of atypical AVNRT (hazard ratio 3.1, P = 0.04). Independent predictors of AVNRT recurrence were age <20 years and female gender (hazard ratios 14.1 and 3.7, respectively). No significant difference in the incidence of late recurrence was observed in patients with or without residual slow-pathway conduction, or according to use of isoproterenol testing or general anesthesia. However, patients with a single echo with recurrence had a significantly larger echo window (median 85 ms) than those without (median 30 ms, P = 0.01).
CONCLUSIONS: This study demonstrates in a large consecutive single-center series that SP ablation using radiofrequency energy is a highly effective procedure with an extremely low risk of inadvertent AV block and a low recurrence rate. We found that single-AV nodal echo beats represented a procedural endpoint that did not predict AVNRT recurrence but that a large echo window is associated with recurrence. Recurrence rates in this series were higher in young women, possibly reflecting a more conservative approach to ablation in this age group. ©2011, The Authors. Journal compilation ©2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569056     DOI: 10.1111/j.1540-8159.2011.03092.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  11 in total

1.  Role of isoproterenol in predicting the success of catheter ablation in patients with reproducibly inducible atrioventricular nodal reentrant tachycardia.

Authors:  Alireza Heydari; Mohammad Tayyebi; Rahmatolah Damanpak Jami; Asgar Amiri
Journal:  Tex Heart Inst J       Date:  2014-06-01

2.  Practice makes perfect: relationship between hospital procedure volume and permanent pacemaker implantation after paroxysmal supraventricular tachycardia ablation.

Authors:  Vratika Agarwal; Neeraj Shah; Kathan Mehta; Anand Agarwal; Jonathan Willner; James Lafferty
Journal:  J Interv Card Electrophysiol       Date:  2017-11-13       Impact factor: 1.900

3.  Catheter ablation of pediatric AV nodal reentrant tachycardia: results in small children.

Authors:  Ulrich Krause; David Backhoff; Sophia Klehs; Thomas Kriebel; Thomas Paul; Heike E Schneider
Journal:  Clin Res Cardiol       Date:  2015-05-17       Impact factor: 5.460

4.  Mechanisms Underlying AF: Triggers, Rotors, Other?

Authors:  David E Krummen; Shrinivas Hebsur; Jon Salcedo; Sanjiv M Narayan; Gautam G Lalani; Amir A Schricker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-04

5.  Cooling dynamics: a new predictor of long-term efficacy of atrioventricular nodal reentrant tachycardia cryoablation.

Authors:  Mario Matta; Matteo Anselmino; Marco Scaglione; Marco Vitolo; Federico Ferraris; Paolo Di Donna; Domenico Caponi; Davide Castagno; Fiorenzo Gaita
Journal:  J Interv Card Electrophysiol       Date:  2016-12-10       Impact factor: 1.900

6.  Electrophysiological predictors of propafenone efficacy in prevention of atrioventricular nodal re-entrant and atrioventricular re-entrant tachycardia.

Authors:  Hrvoje Pintarić; Ivan Zeljković; Zdravko Babić; Mislav Vrsalović; Nikola Pavlović; Hrvojka Bosnjak; Dubravko Petrac
Journal:  Croat Med J       Date:  2012-12       Impact factor: 1.351

7.  Radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia in children and adolescents: a single center experience.

Authors:  Myung Chul Hyun
Journal:  Korean J Pediatr       Date:  2017-12-22

Review 8.  A review of the safety aspects of radio frequency ablation.

Authors:  Abhishek Bhaskaran; William Chik; Stuart Thomas; Pramesh Kovoor; Aravinda Thiagalingam
Journal:  Int J Cardiol Heart Vasc       Date:  2015-06-09

9.  Atrioventricular nodal reentrant tachycardia ablation with radiofrequency energy during ongoing tachycardia: is it feasible?

Authors:  Basri Amasyali; Ayhan Kilic; Kutsi Kabul; Murat Unlu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-11-17       Impact factor: 1.426

10.  Clinical impact of "pure" empirical catheter ablation of slow-pathway in patients with non-ECG documented clinical on-off tachycardia.

Authors:  Shqipe Gerguri; Nikesh Jathanna; Tina Lin; Patrick Müller; Lukas Clasen; Jan Schmidt; Muhammed Kurt; Dong-In Shin; Christian Blockhaus; Malte Kelm; Alexander Fürnkranz; Hisaki Makimoto
Journal:  Eur J Med Res       Date:  2018-03-27       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.